Edition:
India

CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

15.34HKD
22 Sep 2020
Change (% chg)

HK$-0.16 (-1.03%)
Prev Close
HK$15.50
Open
HK$15.50
Day's High
HK$15.60
Day's Low
HK$15.28
Volume
24,192,124
Avg. Vol
45,020,715
52-wk High
HK$18.17
52-wk Low
HK$10.93

Select another date:

Tue, Jun 23 2020

BRIEF-Cspc Pharmaceutical Says Bortezomib For Injection Obtains Drug Registration Approval By Npma Of PRC

* CSPC PHARMACEUTICAL - BORTEZOMIB FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL BY NPMA OF PRC Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Says Co's Drug Obtained Approval From National Medical Products Administration To Conduct Clinical Trials In China

* CO'S DRUG OBTAINED APPROVAL GRANTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION TO CONDUCT CLINICAL TRIALS IN CHINA Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Says Board Approved Proposal For Possible Issue Of RMB Shares Or Chinese Depositary Receipts

* CSPC PHARMACEUTICAL- BOARD APPROVED A PRELIMINARY PROPOSAL FOR POSSIBLE ISSUE OF RMB SHARES OR CHINESE DEPOSITARY RECEIPTS

BRIEF-CSPC Pharmaceutical Posts Qtrly Profit Attributable Rmb1.16 Billion

* CSPC PHARMACEUTICAL - QTRLY PROFIT ATTRIBUTABLE RMB1.16 BILLION VERSUS RMB951.8 MILLION

BRIEF-Cspc Pharmaceutical Says "Docetaxel For Injection (Albumin-Bound)" Got Nod To Conduct Clinical Trials In China

* CSPC PHARMACEUTICAL-"DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)" DEVELOPED BY UNIT GOT APPOVAL GRANTED BY NMPA OF PRC TO CONDUCT CLINICAL TRIALS IN CHINA Further company coverage:

BRIEF-CSPC Pharmaceutical Group Says Ornithine Aspartate Injection Obtains Drug Registration Approval

* ORNITHINE ASPARTATE INJECTION OBTAINED DRUG REGISTRATION APPROVAL GRANTED BY NMPA Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group Says FY Total Revenue RMB22.10 Bln

* RECOMMENDED PAYMENT OF A FINAL DIVIDEND OF HK20 CENTS PER SHARE

Select another date: